Morgan Stanley raised the firm’s price target on Axsome Therapeutics (AXSM) to $190 from $125 and keeps an Overweight rating on the shares.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback